Sök artiklar i SveMed+

Observera: SveMed+ upphör att uppdateras!



Brain-derived neurotrophic factor serum and plasma levels in the treatment of acute schizophrenia with olanzapine or risperidone: 6-week prospective study
Engelsk titel: Brain-derived neurotrophic factor serum and plasma levels in the treatment of acute schizophrenia with olanzapine or risperidone: 6-week prospective study Läs online Författare: Mikulic, Suzan Kudlek ; Mihaljevic-Peles, Alma ; Sagud, Marina ; Janovic, Maja Bajs ; Ganoci, Lana ; Grubisin, Jasmina ; Rojnic, Martina Kuzman ; Cusa, Bjanka Vuksan ; Bradas, Zoran ; Božina, Nada Språk: Eng Antal referenser: 59 Dokumenttyp: Artikel UI-nummer: 18020205

Tidskrift

Nordic Journal of Psychiatry 2017;71(7)513-20 ISSN 0803-9488 E-ISSN 1502-4725 KIBs bestånd av denna tidskrift Denna tidskrift är expertgranskad (Peer-Reviewed)

Sammanfattning

Antipsychotics have been the mainstay of the treatment of schizophrenia, and their potential role in neuroprotection could be related to brain-derived neurotrophic factor (BDNF). So far different effects on both serum and plasma levels of BDNF were reported related to the various antipsychotic treatments. Aim of this study was to investigate the influence of olanzapine or risperidone on both plasma and serum levels of BDNF in patients with acute schizophrenia. For 50 participants with acute episode of schizophrenia both plasma and serum BDNF, along with the Positive and Negative Syndrome Scale (PANSS) and the Clinical Global Impression scale, were assessed pretreatment and post treatment – after 6 weeks of either risperidone or olanzapine. Results show that a weak correlation between pretreatment plasma and serum levels of BNDF was found no longer significant after 6 weeks of treatment. Antipsychotics, olanzapine and risperidone showed no significant effect on post treatment plasma and serum levels of BDNF. Pretreatment plasma level of BDNF and PANSS positive subscale were positively correlated. Post treatment serum level of BDNF and Clinical Global Impression were negatively correlated. In conclusion, plasma and serum BDNF levels could be different markers to some extent with regard to clinical symptoms, response to therapy and outcome. The interrelation between serum and plasma BDNF should be established in further studies.